ArticleClinical rheumatology2004
Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus.
Article in Clinical rheumatology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis.Scientific reports · 2021Pooled it
- IL-18 Promotes the Development of Lupus Nephritis by Activating the Wnt/β-Catenin Signaling Pathway in Renal Tubular Epithelial Cells.Inflammation · 2026Article
- EGFR-STAT1 pathway drives fibrosis initiation in fibroinflammatory skin diseases.Nature communications · 2025Article
- Precision Medicine in Rheumatology: The Role of Biomarkers in Diagnosis and Treatment Optimization.Journal of clinical medicine · 2025Review
- Occurrence of Lupus-Like Nephritis in a Girl With NLRC4 Gain-of-Function Mutations.Kidney international reports · 2024Article
- Evaluation of causal associations between interleukin-18 levels and immune-mediated inflammatory diseases: a Mendelian randomization study.BMC medical genomics · 2023Article
- Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Frontiers in immunology · 2022Review
- Interleukin-18 in Inflammatory Kidney Disease.Frontiers in medicine · 2021Review
- Cytokine clusters as potential diagnostic markers of disease activity and renal involvement in systemic lupus erythematosus.The Journal of international medical research · 2020Observational
- Rapamycin‑induced autophagy attenuates hormone‑imbalance‑induced chronic non‑bacterial prostatitis in rats via the inhibition of NLRP3 inflammasome‑mediated inflammation.Molecular medicine reports · 2019Article
- Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.Frontiers in immunology · 2018Article
- Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients.Medicine · 2016Article
- Article
- IL-18 in inflammatory and autoimmune disease.Cellular and molecular life sciences : CMLS · 2013Review
- Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus.Journal of clinical immunology · 2013Article
- Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus.Rheumatology international · 2012Article
- Biological therapy in systemic lupus erythematosus.International journal of rheumatology · 2012Article
- Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- IL18 polymorphism is associated with Behçet's disease but not lupus in patients from Turkey.The Journal of rheumatology · 2011Article
- Dense mapping of IL18 shows no association in SLE.Human molecular genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine the serum interleukin-18 (IL-18) levels in patients with systemic lupus erythematosus (SLE) and to assess their relationship with disease activity. Thirty-five patients with SLE and 35 age- and sex-matched controls were enrolled in this study. Paired serum samples were collected from all the patients with SLE, both at active stage before treatment and at the stable stage after treatment. The serum IL-18 levels were determined using ELISA and their correlations with the disease activity, measured using the SLE Disease Activity Index (SLEDAI) and laboratory parameters such as anti-dsDNA antibody, CH50, C3, C4, and circulating immune complex levels, were analyzed. The serum IL-18 levels in patients with SLE were significantly higher than those in the controls, particularly when the disease status was active (mean+/-SD: active stage, 721.23+/-360.15 pg/ml; inactive stage, 343.68+/-317.78 pg/ml; controls, 113.98+/-13.22 pg/ml, p<0.05). The IL-18 levels measured at the active stage before treatment correlated well with SLEDAI (r=0.41, p<0.05) and anti-dsDNA antibody titer (r=0.35, p<0.05). When we compared the changes of the IL-18 level and those of parameters reflecting the disease activity between the active stage and the stable stage of the disease, it was found that the changes in IL-18 level correlated well with the changes of SLEDAI score during the patient's disease course (r=0.39, p<0.05). In conclusion, the serum IL-18 levels were elevated in patients with SLE, and these increased levels correlated well with SLE disease activity.
Indexed as
Identifiers
15168150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.